Binding is crucial to the function of most biologically active molecules, but difficult to quantify directly in living tissue. To this end, f luorescence recovery after photobleaching was used to detect the immobilization of f luorescently labeled ligand caused by binding to receptors in vivo. Measurements of mAb affinity to target antigen within human tumor xenografts revealed a saturable binding isotherm, from which an in vivo carcinoembryonic antigen density of 0.56 nmol͞g (5.0 ؋ 10 5 ͞cell) and an association constant of K a 4 ؋ 10 7 M ؊1 were estimated. The present method can be adapted for in vivo studies of cell signaling, targeted drugs, gene therapy, and other processes involving receptor-ligand binding.Specific receptor-ligand binding is crucial to the function of many biologically active molecules and is the basis for a wide range of novel therapeutic and diagnostic strategies. Controversy regarding the performance of receptor-targeting agents (1-3) has arisen, in part, from uncertainties in evaluating binding in situ. In vitro measurements may be misleading due to in vivo differences in receptor density, presentation, and accessibility, and due to microenvironment-related changes in binding kinetics (4-6). We devised a method to measure binding directly at a microscopic level in living tissue by applying fluorescence recovery after photobleaching (FRAP) to detect receptor-mediated immobilization of fluorescently labeled ligand.With the FRAP technique, the movement of fluorescently labeled molecules is made evident by exposing the region of interest to a pulse of focused laser light to create a microscopic photobleached pattern that then dissipates due to local transport phenomena. This approach has been used extensively to detect binding in cell membranes (7,8), cytoplasm (9, 10), and various in vitro preparations (11-16). We previously applied FRAP in vivo to measure the interstitial diffusion and convection of albumin within a tumor tissue preparation (17), and we report here the application of FRAP to measure binding in vivo. Fluorescent ligand is introduced into tissue, and the fluorescence redistribution after laser exposure is recorded as a series of digital images from which the molecular mobility is calculated. Apparent binding affinity K app , the ratio of bound to free ligand, is inferred from the mobility reduction compared with an equivalent nonspecific molecule. An in vivo binding isotherm is then constructed by measuring apparent affinity at various ligand concentrations.
MATERIALS AND METHODSFluorescent Ligand. In this study, the tumor-associated antigen carcinoembryonic antigen (CEA) and the CEAspecific mAb ZCE025 constitute the receptor-ligand system. We examined both bivalent (intact IgG) and monovalent (FabЈ fragment) forms of the ligand. Control measurements were performed using S1, a nonspecific mAb of the same IgG 1 isotype. The antibodies (provided by Hybritech) were labeled with fluorescein (Molecular Probes) at approximate molar ratios of 6 per IgG and 2.3 per FabЈ. A...